HIV and viral hepatitis C coinfection in people who inject drugs: implications of new direct acting antivirals for hepatitis C virus treatment.

Abstract

PURPOSE OF REVIEW:

The recent major shift toward oral direct acting hepatitis C virus (HCV) treatments has the potential to revolutionize the global response to HCV. People who inject drugs (PWID) are a large key affected population who stand to benefit from these new medications.

RECENT FINDINGS:

There is a large number of new drug classes and targets with activity against HCV. Although effective for HCV treatment in monoinfection and coinfection with HIV, most direct-acting antivirals (DAAs) remain within the research pipeline, with only two having achieved regulatory approval to date. Clinical trial data are not available regarding HCV treatment for PWID with DAAs. This article reviews clinical data on HCV treatment for a number of promising compounds in HCV monoinfection and coinfection with HIV and discusses the barriers facing PWID in scale-up and roll-out of DAAs in the coming years.

SUMMARY:

DAAs have the potential to revolutionize HCV treatment. There will be significant access barriers for people who inject drugs to these new medications.

• Authors: Nick Walsh, Lisa Maher
• Journal: Current opinion in HIV and AIDS (Curr Opin HIV AIDS) Vol. 7 Issue 4 Pg. 339-44 (Jul 2012) ISSN: 1746-6318 [Electronic] United States
• PMID: 22498482 (Publication Type: Journal Article, Review)

Chemical References

• Antiviral Agents

Topics

• Administration, Oral
• Antiviral Agents (administration & dosage)
• Coinfection (epidemiology)
• HIV Infections (complications, epidemiology)
• Hepatitis C (complications, drug therapy, epidemiology)
• Humans
• Substance Abuse, Intravenous (complications)
• Treatment Outcome